Get the Stockscreener App
51.83
0.26%
-0.1231
Mirum Pharmaceuticals Inc stock is traded at $51.83, with a volume of 108.80K.
It is down -0.26% in the last 24 hours and up +2.93% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$51.95
Open:
$51.86
24h Volume:
108.80K
Relative Volume:
0.26
Market Cap:
$2.57B
Revenue:
$379.25M
Net Income/Loss:
$-77.34M
P/E Ratio:
-32.15
EPS:
-1.6122
Net Cash Flow:
$-27.87M
1W Performance:
-0.32%
1M Performance:
+2.93%
6M Performance:
+10.91%
1Y Performance:
+31.08%
1-Day Range:
$50.96
$52.05
1-Week Range:
$50.96
$53.59
52-Week Range:
$36.20
$54.78
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
51.84 | 2.64B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.61 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.70 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.61 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
573.86 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.62 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
What analysts say about Mirum Pharmaceuticals Inc. stockAccelerated capital growth - jammulinksnews.com
What drives Mirum Pharmaceuticals Inc. stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com
Mirum Pharmaceuticals Inc. Stock Analysis and ForecastExceptional profit velocity - jammulinksnews.com
Purpose, not just product: What sets Mirum apart - Endpoints News
Bank of New York Mellon Corp Acquires 122,402 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2025 Earnings Call Transcript - MSN
Is Mirum Pharmaceuticals Inc. a good long term investmentPhenomenal wealth increase - Autocar Professional
Mirum Pharma’s Rare Disease Bets Are Paying Off For Investors - Finimize
Mirum Gains 35% in 3 Months: How Should You Play the Stock? - MSN
Teacher Retirement System of Texas Sells 925 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals Advances Phase 3 Study on Maralixibat for Cholestatic Pruritus - TipRanks
When the Price of (MIRM) Talks, People Listen - news.stocktradersdaily.com
How Mirum Pharmaceuticals Inc. stock performs during market volatilityEntry Level Low Risk Picks - Newser
What makes Mirum Pharmaceuticals Inc. stock price move sharplyFree Access to Investment Community - Newser
Why Mirum Pharmaceuticals Inc. stock attracts strong analyst attentionMarket Beating Strategy - Newser
Mirum Pharmaceuticals stock hits all-time high at $54.46 - Investing.com Australia
Mirum Hits All-Time HighIs There More Upside Ahead? - RTTNews
Mirum Pharmaceuticals stock hits all-time high at $54.46 By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals price target raised to $76 from $68 at Evercore ISI - MSN
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Allspring Global Investments Holdings LLC - Defense World
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
KBC Group NV Makes New Investment in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Top Analyst Ratings From Last Week - The Globe and Mail
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Is Breakeven Near? - 富途牛牛
Mirum Pharmaceuticals (NASDAQ:MIRM) Lowered to Hold Rating by Wall Street Zen - Defense World
Mirum Pharmaceuticals beats Q1 estimates, raises 2025 guidance; shares rise - Investing.com Nigeria
Wealth Enhancement Advisory Services LLC Purchases 339 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals Insiders Sold US$2.2m Of Shares Suggesting Hesitancy - simplywall.st
Mirum Pharmaceuticals, Inc.(NasdaqGM: MIRM) dropped from Russell 3000E Index - MarketScreener
Mirum Pharmaceuticals, Inc.(NasdaqGM: MIRM) dropped from Russell Microcap Index - MarketScreener
When (MIRM) Moves Investors should Listen - news.stocktradersdaily.com
Rhumbline Advisers Purchases 2,321 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Where are the Opportunities in (MIRM) - news.stocktradersdaily.com
Insider Sell: William Fairey Sells Shares of Mirum Pharmaceutica - GuruFocus
High Growth Tech Stocks In The US Market - Yahoo Finance
Cantor Fitzgerald Predicts MIRM FY2026 Earnings - Defense World
Mirum Pharmaceuticals Expands Team with 10 New Hires, Grants $5.7M Stock Options Package - Stock Titan
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? - Yahoo Finance
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.06 Million Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):